Amedisys Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Mizuho Securities Upgrades Amedisys (AMED) to Buy; Pay Up for Strong Management
May 3, 2017 7:30 AM EDTMizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $65.00.
Analyst Sheryl Skolnick is positive on management amid Q1 results. "AMED's 1Q17 result demonstrates just that: not only are cost savings real, but the balanced approach to... More
